Triple-negative breast cancer: A short review

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 6, 2010, Pages 637-645

  Elias, Anthony D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Breast cancer; Review; Triple negative

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; IC 50; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650032040     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181b8afcf     Document Type: Review

References (63)

1. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triplenegative breast cancer. Cancer. 2007;109:25-32.
2. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2- negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer. 2007; 109:1721-1728.
3. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
4. Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006;8:R66.
5. Adebamowo CA, Ogundiran T, Akang E. Epidemiology of triple negative breast cancer in Nigerian women [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2006;24:568S.
6. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large wellcharacterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-350.
7. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
8. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumorsubtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
9. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
10. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11: 5678-5685.
11. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59: 225-231.
12. Kusinska R, Potemski P, Jesionek-Kupnicka D, et al. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma -relation with grade, stage, estrogen receptor and HER2. Pol J Pathol. 2005;56:107-110.
13. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729-735.
14. Herr A, Gluz O, Ting E, et al. Biological characteristics in triple negative high risk breast cancer and their clinical implications [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2006;24:703S.
15. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671.
16. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495-506.
17. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
18. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846-5853.
19. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126-2132.
20. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652-5657.
21. Liedtke C, Mazouni C, Hess KR, et al. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2007;25:569S.
22. Rhee J, Oh S, Oh D, et al. Does triple-negative breast cancer (TNBC) have distinct clinicopathologic characteristics and prognostic significance [ASCO Annual Meeting Proceedings Part I]? J Clin Oncol. 2007;25:736S.
23. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13: 2329-2334.
24. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
25. Cazzaniga ME, Mustacchi G, Pronzato P, et al. Pathological characteristics and clinical outcome in triple-negative breast cancer (BC) patients (PTS): Results from the NORA study [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2007;25:595S.
26. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007;9:R16.
27. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4.
28. Marty ME, Guinebretiere J, Mathieu M, et al. Triple-negative phenotype is a strong predictor of sensitivity to epirubicin-cyclophosphamide (EC) then docetaxel (D) (ECD) primary chemotherapy (PCT) for localized breast cancer [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2007;25:739S.
29. Nitz UA, Gluz O, Herr A, et al. Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: A hypothesis generating study [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2006;24:44S.
30. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
31. Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC) [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2006;24:5S.
32. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005;5:388-393.
33. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 2000;275:23899-23903.
34. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001;61:4842-4850.
35. Leong CO, Vidnovic N, DeYoung MP, et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 2007;117:1370-1380.
36. Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). Breast Cancer Res Treat. 2006;106: 100.
37. Cisplatin as First Line Therapy for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker Response. ClinicalTrials.gov identifier NCT00483223.
38. Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer. ClinicalTrials.gov identifier NCT00321633.
39. Triple Negative Trial: A Randomized Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Advanced Oestrogen Receptor- Progesterone Receptor-Human Epidermal Growth Factor Receptor Two- Breast Cancer. ClinicalTrials.gov identifier NCT00532727.
40. Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol. 2002;33:863-870.
41. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57:963-969.
42. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5(suppl 1):37-44.
43. Carvalho I, Milanezi F, Martins A, et al. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumor progression. Breast Cancer Res. 2005;7:788-795.
44. Tsuda H, Tani Y, Weisenberger J, et al. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Cancer Sci. 2005;96:333-339.
45. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
46. Roussidis AE, Theocharis AD, Tzanakakis GN, et al. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr Med Chem. 2007;14:735-743.
47. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-1816.
48. Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer. ClinicalTrials.gov identifier NCT00246571.
49. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67:2226-2238. (Pubitemid 46424242)
50. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105:319-326.
51. A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple- Negative' Breast Cancer. ClinicalTrials.gov identifier NCT00371254.
52. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
53. Bevacizumab and Abraxane as Second-Line Therapy in Triple Negative Metastatic Breast Cancer. ClinicalTrials.gov identifier NCT00472693.
54. Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer. ClinicalTrials.gov identifier NCT00479674.
55. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007;16:104-107.
56. Corkery B, O'Donovan N, Clynes M, et al. Epidermal growth factor receptor(EGFR) inhibition in triple-negative breast cancer (BrCa) [ASCO Annual Meeting Proceedings Part I]. J Clin Oncol. 2007;25:617S.
57. Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer. ClinicalTrials.gov identifier NCT00232505.
58. Carey LA, Mayer E, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Breast Cancer Res Treat. 2007;106:106.
59. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat. 2007;106:S32.
60. Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer. ClinicalTrials.gov identifier NCT00491816.
61. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
62. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27(Suppl):803s [abstr. CRA501].
63. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/ carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009;27(Suppl):793s [abstr. 3].